European Innovation Council

Brevel develops innovative cultivation technology for sustainable, low-cost production of microalgae. Its high-tech, indoor, automated systems use internal illumination to achieve over 90% cost reduction and up to 200 times higher yields compared to traditional methods. Brevel targets various markets where microalgae-derived products are in demand.

Precisionlife employs a unique approach to drive innovation in chronic diseases through precision medicine. It uses artificial intelligence to generate deep insights into disease biology, stratifying patient populations for novel drug targets, biomarkers, and repositioning candidates.

Founded in 2012, Stablepharma specializes in developing processes for vaccine stabilization. Its flagship product, Stablevax, enables precise dosage pre-loading into syringes at manufacture, eliminating wastage. The company's technology platform converts existing vaccines and diagnostics into thermostable products, addressing global cold chain challenges.

AlzeCure Pharma is a Swedish pharmaceutical company dedicated to developing drug therapies targeting diseases affecting the central nervous system. Its primary focus lies in Alzheimer's disease, with five drug candidates at various stages of development.

QDI Systems B.V. is a startup based in Groningen, the Netherlands, focused on developing advanced imaging devices for medical applications using quantum dot technology. The company specializes in creating X-ray sensors that deliver high-contrast and high-resolution imaging, particularly for mammography, while also reducing radiation exposure for patients. QDI Systems aims to provide user-friendly quantum dot materials accompanied by comprehensive instructions for constructing high-performance imaging devices. By leveraging innovative technology, the company enhances the precision of medical imaging, enabling healthcare professionals to obtain critical diagnostic information efficiently and safely.

QDI Systems B.V. is a startup based in Groningen, the Netherlands, focused on developing advanced imaging devices for medical applications using quantum dot technology. The company specializes in creating X-ray sensors that deliver high-contrast and high-resolution imaging, particularly for mammography, while also reducing radiation exposure for patients. QDI Systems aims to provide user-friendly quantum dot materials accompanied by comprehensive instructions for constructing high-performance imaging devices. By leveraging innovative technology, the company enhances the precision of medical imaging, enabling healthcare professionals to obtain critical diagnostic information efficiently and safely.

Elicera Therapeutics is a clinical-stage immuno-oncology company based in Sweden that focuses on developing innovative cell and gene therapies to treat cancer. The company’s portfolio includes four drug candidates: two oncolytic virus therapies, ELC-100 and ELC-201, and two CAR T-cell treatments, ELC-301 and ELC-401. Additionally, Elicera has developed a universal CAR T-cell technology platform named iTANK (ELC-001), designed to enhance the efficacy of CAR T-cell therapies by enabling a multi-targeted approach against solid tumors. With its commitment to advancing immune-based cancer treatments, Elicera Therapeutics aims to improve outcomes for patients facing various forms of cancer.

Aplagon is a biopharmaceutical company focused on the development of innovative antithrombotic compounds aimed at addressing unmet medical needs in patients experiencing complications from vascular interventions. The company specializes in creating biological mimetics of heparin proteoglycan, which are designed to effectively manage thrombotic occlusions and ischemic reperfusion injuries associated with vascular injuries. By prioritizing safety and efficacy, Aplagon seeks to deliver antithrombotic therapies that offer significant advantages over existing treatments, ultimately improving patient outcomes in challenging medical scenarios.

TENSIVE s.r.l. is a biomedical company based in Milan, Italy, founded in 2012. It specializes in the development of innovative prostheses for natural breast reconstruction and augmentation. The company's products utilize biodegradable synthetic biomaterials and feature an internal micro-architecture that mimics blood vessel structures. These vascularized prostheses aim to enhance the quality of life for patients undergoing treatment for breast cancer, offering a solution that reduces the need for recurrent and costly surgical interventions. Through its focus on advanced biomaterials and design, TENSIVE seeks to provide effective and sustainable options for breast reconstruction.

Hervolution Therapeutics specializes in developing first-in-class immunotherapies targeting tumors by harnessing Human Endogenous Retroviral proteins (HERVs). The company pioneers innovative biotechnology solutions to combat hidden enemies within the human body.

FibriTech develops a biomaterial technology producing sustainable, natural fiber-based materials for industrial and agricultural applications. Their products include eco-friendly alternatives to rock wool, glass wool, and foamed plastics, serving construction and horticulture sectors.

Inbrain Neuroelectronics is a medical device company that designs and commercializes graphene-based neural interfaces and intelligent neuromodulation systems to treat brain disorders. The core platform is an implantable system that decodes brain activity with high resolution and provides focal, adaptive stimulation, enabling real-time precision neurology and autonomous therapy adjustments. This approach aims to maximize therapeutic outcomes while minimizing side effects for conditions such as Parkinson’s disease, epilepsy, and stroke rehabilitation. The company pursues strategic collaborations to extend its solutions to peripheral nerve and systemic disease applications, expanding the potential of neurotechnology and bioelectronics.

Founded in 2013 by Walter Sanseverino and Riccardo Aiese Cigliano, Sequentia Biotech is a bioinformatics company that transforms genomic data into actionable knowledge for academic research, plant/animal breeding, and biomedicine. With over 30 clients and partners, including public/private research centers, companies, and hospitals, Sequentia participates in more than 160 R&D projects and maintains two open-source biodata banks.

Oryl Photonics specializes in developing laboratory instruments for pharmaceutical and biotech companies. Their core product provides a simple, reliable, and cost-effective method for measuring solubility, contributing to accelerated drug development and improved medicine. The company's unique technology preserves valuable substances during testing, offering a solubility measurement service that empowers researchers to make data-driven decisions and expedite product development.

Onego Bio is a biotechnology company focused on producing animal-free egg white protein through precision fermentation. Their flagship product, Bioalbumen, offers a sustainable alternative to traditional egg proteins, boasting identical taste and nutritional profiles while providing superior functional properties and a significantly reduced environmental footprint. By employing commercially proven technology, Onego Bio meets the growing demand for stable and sustainable functional ingredients within the food industry. The company has gained recognition as a leader in innovation, winning Fast Company’s 2023 World Changing Ideas award. Additionally, Onego Bio is actively involved in the industry as a co-founder of the Precision Fermentation Alliance and Food Fermentation Europe, further establishing its commitment to advancing sustainable food solutions.

MediWound Ltd. is an integrated biopharmaceutical company based in Yavne, Israel, that specializes in developing, manufacturing, and commercializing innovative therapeutic products for severe burns and chronic wounds. Founded in 2000, the company is known for its flagship product, NexoBrid, which is an FDA-approved biopharmaceutical designed for the removal of eschar in adults with deep partial- and full-thickness thermal burns, offering a less invasive alternative to surgical interventions. MediWound also advances other product candidates, including EscharEx, which has completed Phase II clinical trials for the debridement of chronic and hard-to-heal wounds, and MWPC003 for connective tissue disorders. The company aims to address significant unmet medical needs in these areas and improve patient outcomes.

MediWound Ltd. is an integrated biopharmaceutical company based in Yavne, Israel, that specializes in developing, manufacturing, and commercializing innovative therapeutic products for severe burns and chronic wounds. Founded in 2000, the company is known for its flagship product, NexoBrid, which is an FDA-approved biopharmaceutical designed for the removal of eschar in adults with deep partial- and full-thickness thermal burns, offering a less invasive alternative to surgical interventions. MediWound also advances other product candidates, including EscharEx, which has completed Phase II clinical trials for the debridement of chronic and hard-to-heal wounds, and MWPC003 for connective tissue disorders. The company aims to address significant unmet medical needs in these areas and improve patient outcomes.

iOnctura is a biopharmaceutical company specializing in the development of novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which plays a significant role in cancer progression. The company seeks to enhance existing immune checkpoint therapies by creating new drugs that, when used in conjunction with these therapies, may improve safety and efficacy for cancer patients. iOnctura has formed strategic partnerships with prominent organizations, including Merck and Cancer Research Technology, to advance a pipeline of preclinical molecules toward clinical application. With access to advanced drug discovery labs and a network of academic collaborators, iOnctura is well-equipped to develop innovative combination therapies in the realm of cancer immunology, ultimately striving to optimize treatment outcomes for patients.

ProFuse Technology develops cultured meat production technology that accelerates muscle fiber growth, shortens production time, and increases yield and production capacity, with the aim of improving meat quality and consistency while reducing costs for producers by streamlining the manufacturing process and enabling higher-throughput production of cultured meat.

BOYDSense is a medical device company founded in 2015 and headquartered in South San Francisco, California. The company specializes in developing non-invasive and affordable tools for measuring critical biomarkers through exhaled breath. BOYDSense focuses on breath-based metabolomics, which involves capturing, identifying, and quantifying volatile organic compound (VOC) biomarker patterns found in human breath. This innovative approach enables medical professionals to simplify the monitoring, screening, and risk stratification of chronic diseases, facilitating more effective diagnosis and ongoing management of these conditions.

RS Research is a clinical-stage biotechnology company focused on developing nanomedicines for cancer treatment. Based in Istanbul, Turkey, it has developed a proprietary Sagitta drug-delivery platform that enables targeted chemotherapies across multiple indications. The company advances a portfolio of nanomedicine candidates through preclinical and clinical stages, with its lead program RS-0139 studied in Phase I oncology trials and supported by a GMP-certified production facility for clinical batch drug candidates. RS Research collaborates with international partners on co-development projects and offers ancillary services such as preclinical absorption, distribution, metabolism, and excretion testing, bioanalytical method development and validation, impurity and metabolite analysis, stability testing, toxicology studies, and patent-related due diligence and drafting support. The business aims to deliver targeted therapies with improved therapeutic indices through its nanocarrier technology and partnerships.

Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The company develops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures. Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization.

FreezeM is a company focused on advancing the use of insects as a sustainable protein source for the animal feed industry. Recognizing the potential of insects to address the growing demand for alternative protein, FreezeM develops innovative preservation technologies that facilitate large-scale freezing of insect species. This process aims to create a reliable supply of ready-to-use suspended neonates and frozen eggs, akin to agricultural seed production, which can overcome challenges related to availability, cost, and regulatory constraints. By establishing global stocks of beneficial insects, FreezeM supports various applications, including protein for animal feed, biological pest control, and species preservation, ultimately contributing to a more sustainable food system.

Palobiofarma is a Spanish biotechnology company based in Barcelona, focused on discovering and developing new medicines by modulating adenosine receptors. It aims to be a leader in European adenosine receptor drug discovery, using medicinal chemistry and in vitro pharmacology to identify selective adenosine receptor modulators, with potential applications in treating advanced prostate cancer.

NETRIS Pharma S.A.S. is a biotechnology company based in Lyon, France, focused on the identification and development of therapeutic molecules aimed at treating various forms of cancer. Established in 2008, the company specializes in targeting dependence receptors, which are trans-membrane proteins that play a crucial role in cellular signaling and tumor control. NETRIS Pharma conducts both in vitro and in vivo research, as well as preclinical practices, to manufacture drugs specifically for the treatment of breast cancer, lung cancer, glioblastoma, and neuroblastoma. Through its innovative approach, the company aims to advance cancer therapies and contribute to improved patient outcomes in the pharmaceutical industry.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing innovative treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating novel antibacterial resistance-breakers, including stand-alone inhibitors of bacterial metalloenzymes. These inhibitors are designed to be combined with existing antibiotics, such as carbapenems, to restore their efficacy against the most challenging pathogens responsible for life-threatening infections, including carbapenem-resistant nosocomial pneumonia. Antabio aims to address significant unmet medical needs in the treatment of drug-resistant infections, ultimately providing healthcare professionals with effective medicinal products to combat these critical health challenges. The company has been recognized for its work, receiving a Wellcome Trust Seeding Drug Discovery Award.

RespiQ is a healthtech company developing portable, non-invasive breath analysis technology that uses emission spectroscopy and artificial intelligence to detect biomarkers in breath for early identification and real-time monitoring of respiratory diseases such as COPD, as well as other conditions like asthma, lung cancer, and infectious diseases. Its device aims to be affordable and user-friendly, democratizing access to advanced diagnostics, while its platform can also identify digestive issues through breath biomarkers and support personalized guidance via an app that analyzes a digital breath print to deliver diet and health insights, enabling individuals to monitor changes and improve health outcomes.

NEOGAP Therapeutics is a clinical-stage biopharmaceutical startup focused on immuno oncology. Their pharmaceutical product, personalized tumor trained lymphocytes, offers even one customized cell treatment that is meant to precisely target and destroy cancer in a tailored environment, with very minor side effects.

ResoTher Pharma is a privately held biotechnology company based in Copenhagen, Denmark. The company specializes in developing peptide-based drugs derived from Annexin A1, an endogenous immunomodulator. These drugs are designed as resolution therapies for diseases where neutrophil-driven inflammation is a key pathological factor. ResoTher Pharma's primary focus is on addressing cardiovascular and inflammatory disorders that have significant unmet medical needs. Their patented peptide drugs target a G-protein coupled receptor expressed on leukocytes, aiming to mimic the body's natural response to resolving inflammation and promoting tissue repair.

Founded in 2017, SolasCure is a biotechnology company based in Wales, UK. It specializes in developing innovative hydrogel treatments for patients with chronic wounds. Its flagship product, Aurase, facilitates wound debridement, removing dead or infected tissue to enhance healing.

FarmInsect GmbH, established in 2019 and headquartered in Bergkirchen, Germany, specializes in automated insect breeding systems. The company develops machines and IoT solutions that enable regional farmers to rear insects on-site for use as animal feed, primarily for chickens, pigs, and fish. This sustainable approach aims to replace imported soy or fishmeal with locally produced protein feed, thereby enhancing the efficiency of animal husbandry while reducing environmental impact.

Founded in 2014, Cellevate specializes in developing advanced 3D cell culture systems using nanofiber technology. Its patented platform enables the creation of consistent and porous networks of nanofibers, serving as realistic in-vitro models for scientific research and development across various industries.

Lithos Crop Protect is a producer of non-toxic, biological, and highly effective crop protection products and solutions intended to help crop growers control pests and protect agriculture. They are developing an active ingredient that can make a significant contribution to preventing the spread of the corn rootworm in rapidly advancing products for the agriculture industry.

Epigene Labs SAS is a biotechnology firm focused on enhancing precision oncology through its advanced technology platform that utilizes artificial intelligence. Founded in 2019 and headquartered in Paris, France, with an additional office in Boston, Massachusetts, the company addresses the significant challenges of aggregating, analyzing, and visualizing extensive genomic data in cancer research. By integrating proprietary data from partners with publicly available datasets, Epigene Labs provides medical researchers with actionable insights and user-friendly analytics. The company collaborates with leading cancer centers and prominent biotech firms to develop intelligence-augmenting services that support drug discovery and research in precision oncology. Its innovative approach aims to transform genomic data into effective strategies for targeted cancer therapies.

RUBYnanomed provides non-invasive monitoring of cancer progression. They enable the analysis of their phenotypic, genetic, and functional characteristics, facilitating unprecedentedly frequent monitoring of cancer progression in a minimally invasive, cost-efficient way. They enable oncologists to detect and analyze the evolution of cancer subtypes and therapeutic resistance mechanisms in each patient, providing personalized therapy insights to treat their patients.

Xeltis is a clinical-stage medical device company developing bio-absorbable heart valves and blood vessels. Its RestoreX technology enables the body's natural healing system to create functional tissue within its devices, forming new valves or vessels over time. Headquartered in Zurich, Switzerland, with R&D and manufacturing facilities in Eindhoven, Netherlands, Xeltis aims to transform cardiovascular care.

Inbrain Neuroelectronics is a medical device company that designs and commercializes graphene-based neural interfaces and intelligent neuromodulation systems to treat brain disorders. The core platform is an implantable system that decodes brain activity with high resolution and provides focal, adaptive stimulation, enabling real-time precision neurology and autonomous therapy adjustments. This approach aims to maximize therapeutic outcomes while minimizing side effects for conditions such as Parkinson’s disease, epilepsy, and stroke rehabilitation. The company pursues strategic collaborations to extend its solutions to peripheral nerve and systemic disease applications, expanding the potential of neurotechnology and bioelectronics.

Genomika Lietuva is a business that provides cutting-edge, perceptive, and meticulously optimized solutions for the biomedical sciences. It creates DNA storage technologies that allow for high-density storage of significant amounts of information in a remarkably tiny area.

Pulse is a platform for furthering our understanding of bioprinting and its applications in space exploration and medicine.

Scipio Bioscience SAS is a biotechnology company based in Paris, France, founded in 2017. It specializes in manufacturing benchtop kits that provide innovative sample preparation solutions for single-cell studies. These kits are designed for use in sequencing applications across both clinical and basic research, with a particular focus on transcriptomics. Scipio Bioscience's products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating more precise and efficient analysis in various scientific investigations.

Elgan Pharma is a biotechnology company specializing in neonatology, primarily focused on addressing the medical challenges faced by premature infants. The company develops innovative therapies using nanotechnology aimed at preventing visual impairment, a significant concern for preterm babies. By targeting the multifactorial causes of visual disabilities, Elgan Pharma enables healthcare professionals to improve visual outcomes and reduce the risk of long-term disabilities in this vulnerable population. Through its advancements in late-stage development, the company is committed to enhancing the quality of care for premature infants and addressing critical developmental difficulties associated with their early birth.

ADmit Therapeutics is a biotechnology company that develops diagnostic tests for early detection of Alzheimer’s disease. Its blood-based assay uses epigenetic analysis to assess mitochondrial DNA methylation, including methylcytosines, through next-generation sequencing, and does not rely on beta-amyloid or tau markers. The test is intended to aid pharmaceutical research by enabling early diagnosis and streamlined drug development. The company was founded in 2017 and is based in Begues, Spain.

Plasmacure develops a cold plasma technology to treat chronic wounds, with a focus on diabetic foot ulcers. Based in Eindhoven, the Netherlands, the company aims to stimulate healing by killing bacteria, promoting cell proliferation, and improving microcirculation, thereby reducing the risk of amputation and enhancing patient quality of life.

Cellbox Solutions is a technology company that specializes in innovative logistic solutions for the global BioMed industry. It has developed a carbon dioxide incubator designed for the storage, isolation, handling, and analysis of biological materials. This incubator offers essential logistic services and ensures the proper handling of living cells, facilitating their storage, reproduction, transportation, and analysis. By enabling the transportation of living cells via various methods, including road, rail, and air, Cellbox Solutions supports healthcare providers in their efforts to deliver the latest therapies to patients.

InProTher Aps is a biotechnology company based in Copenhagen, Denmark, focusing on the development of innovative vaccine technologies and candidates within the field of immunotherapy. Established in 2011, the company is dedicated to creating the first adaptive immune therapy that targets immunosuppressive genes associated with ancient retroviruses. InProTher is also engaged in the development of products aimed at combating HIV, papilloma viruses, and various forms of cancer. Through its research and development efforts, InProTher seeks to advance treatment options in the evolving landscape of immunotherapy.

Scandinavian Real Hearts is a medical technology company developing an artificial heart to address the needs of patients awaiting heart transplantation. Its Total Artificial Heart is designed to closely resemble the shape, function, and blood flow of the human heart, with the aim of serving as a bridging solution for transplant candidates.

Founded in 2019, Arthex Biotech is a Spanish biotechnology company specializing in the development of antisense RNA therapies for genetic diseases. The company, spun off from the University of Valencia, leverages its team's expertise in drug discovery and microRNAs to create innovative treatments.

3DSecret is developing cutting-edge technologies to uncover the stochastic patterns behind metastasis in order to predict the course of cancer.

Abbelight is a company that develops modular single-molecule localization microscopy technology to enable super-resolved fluorescence imaging for biological research. Its solution combines consumables, hardware, and software to deliver reliable, state-of-the-art imaging and supports researchers in biology, pharmacology, and environmental science who seek higher-resolution observations of biological samples. The modular platform enables researchers to implement SMLM without compromising instrument performance, and the company provides end-to-end support from sample preparation to data analysis by integrating chemistry, software, and optical components. By simplifying workflows and offering integrated tools, Abbelight aims to make advanced microscopy accessible to laboratories of varying sizes, helping users observe subcellular structures with improved resolution.

Norbite is a biotechnology research firm that specializes in converting plastic waste into sustainable products through an innovative insect-based biorefinery process. The company's technology enables the production of sustainable goods by utilizing larvae that are bio-refined to extract proteins suitable for food and animal feed. By focusing on the transformation of plastic waste, Norbite aims to provide environmentally friendly solutions while addressing the growing concerns of waste management and sustainability. Through its unique approach, the firm contributes to the development of sustainable products and services that benefit both clients and the environment.

Inobiostar focuses on research and experimental development services.

Smart Immune is a clinical‑stage biotechnology company developing next‑generation hematopoietic stem cell–based biotherapies to improve outcomes for patients with severe diseases. Its flagship program uses T‑cell progenitors (ProTcells) to enable rapid, polyclonal, and safe immune reconstitution after transplantation. The platform integrates targeted conditioning, gene therapy, and genome editing to extend treatment options for inherited blood disorders, blood cancers, and other life‑threatening conditions.

Samplix is a biotechnology company based in Herlev, Denmark, that specializes in advanced sample preparation for single DNA and RNA molecules. The company has developed the proprietary Xdrop™ technology, which utilizes a unique "water-oil-water" droplet formation to create millions of reaction chambers for handling individual DNA molecules. This innovative technology allows for targeted enrichment of large DNA fragments, addressing the limitations of existing multi-molecule preparation methods. By enabling precise and sensitive sample preparation, Samplix empowers researchers to conduct more informed studies, facilitating the sequencing of genetic regions critical for understanding virus integration and minimizing unintended CRISPR edits. The Xdrop™ system includes both the instrumentation and consumables needed for effective single-molecule analysis, thereby enhancing the ease of use and efficiency in molecular research.

Samplix is a biotechnology company based in Herlev, Denmark, that specializes in advanced sample preparation for single DNA and RNA molecules. The company has developed the proprietary Xdrop™ technology, which utilizes a unique "water-oil-water" droplet formation to create millions of reaction chambers for handling individual DNA molecules. This innovative technology allows for targeted enrichment of large DNA fragments, addressing the limitations of existing multi-molecule preparation methods. By enabling precise and sensitive sample preparation, Samplix empowers researchers to conduct more informed studies, facilitating the sequencing of genetic regions critical for understanding virus integration and minimizing unintended CRISPR edits. The Xdrop™ system includes both the instrumentation and consumables needed for effective single-molecule analysis, thereby enhancing the ease of use and efficiency in molecular research.

Smart Immune is a clinical‑stage biotechnology company developing next‑generation hematopoietic stem cell–based biotherapies to improve outcomes for patients with severe diseases. Its flagship program uses T‑cell progenitors (ProTcells) to enable rapid, polyclonal, and safe immune reconstitution after transplantation. The platform integrates targeted conditioning, gene therapy, and genome editing to extend treatment options for inherited blood disorders, blood cancers, and other life‑threatening conditions.

Nemysis is a Dublin-based specialty pharmaceutical company focused on developing and manufacturing food supplements, medical matrix products and prescription medicines. Founded in 2005, it pursues a staged development strategy to commercialize OTC and prescription products across different market segments addressing nutritional disorders and deficiencies. The company develops products such as a novel nanoparticulate oral iron supplement with a unique absorption mechanism to treat iron deficiency or anemia while minimizing gastrointestinal side effects, and glutenase capable of functioning in both the stomach and intestine to protect individuals with celiac disease or gluten sensitivity from inadvertent gluten exposure.

Inbiome is a trailblazing company in molecular diagnostics, specializing in proprietary molecular culture technology. This innovation enables swift bacterial testing and microbiome analysis, significantly expediting the process compared to traditional methods. The company's primary mission is to advance clinical microbiology by focusing on microbial detection and product development, thereby guiding clinicians towards more accurate and timely diagnoses. By offering advanced molecular technology for microbiome analysis, Inbiome aids in enhancing the understanding of bacteria in the human body, facilitating correct treatments, and mitigating unnecessary complications, costs, and anti-microbial resistance.

Molecular Attraction is a research and development firm focused on creating innovative solutions for vector-borne disease control and eradication. The company specializes in identifying biological compounds that can influence the behavior of various vector organisms, including mosquitoes, ticks, flies, and rodents. By utilizing sustainable technology and chemical blends, Molecular Attraction aims to provide effective, long-lasting, and low-maintenance pest control solutions. Their approach is designed to enhance the efficacy of vector-borne disease management while prioritizing environmental sustainability and cost-effectiveness within the pest control industry.

IDloop develops and sells a contactless fingerprint sensor solution, utilizing 3D imaging, AI, and embedded technology. This solution is designed for business and government markets, offering secure multi-finger image capture to enhance security services.

Valo Therapeutics is an immunotherapy company focused on developing antigen-coated oncolytic viruses as therapeutic vaccines for cancer treatment. Founded in 2016 and based in Oxford, United Kingdom, with an additional office in Helsinki, Finland, the company utilizes its innovative Valo Tx platform, which includes PeptiCRAd, an engineered human oncolytic adenovirus. This platform is designed to induce systemic anti-tumor T cell responses by transforming oncolytic adenoviruses into targeted, tissue-specific cancer vaccines without requiring the production of multiple genetically modified viruses. Valo Therapeutics is also advancing other neoantigen strategies, including PeptiENV, in collaboration with Professor Vincenzo Cerullo from the University of Helsinki, to enhance therapeutic responses against various cancer types.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses to enhance T-cell therapies for cancer treatment. Established in 2013, the company focuses on utilizing its patented technology to improve tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibiting antibody treatments. TILT Biotherapeutics is advancing products such as TILT-123, TILT-234, and TILT-321, which aim to modify the tumor microenvironment and boost immune responses against cancer. The company's innovative approach holds promise for achieving effective results in treating solid tumors, paralleling the successes seen in hematological tumors.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses to enhance T-cell therapies for cancer treatment. Established in 2013, the company focuses on utilizing its patented technology to improve tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibiting antibody treatments. TILT Biotherapeutics is advancing products such as TILT-123, TILT-234, and TILT-321, which aim to modify the tumor microenvironment and boost immune responses against cancer. The company's innovative approach holds promise for achieving effective results in treating solid tumors, paralleling the successes seen in hematological tumors.

Iris.ai offers an AI-powered science assistant designed for R&D departments. It enhances research efficiency through smart search, filters, summaries, and autonomous extraction of scientific insights.

N2 Applied is a Norwegian technology company focused on enabling farmers to produce their own sustainable fertilizer through an innovative process that utilizes slurry, air, and electricity. The company is in the pre-commercial phase and has developed a technology that allows for the local production of nitrogen-rich fertilizer from liquid organic substrates, such as livestock manure. By integrating nitrogen from the atmosphere into these substrates, N2 Applied's solution not only enhances the nitrogen content but also mitigates ammonia loss and reduces greenhouse gas emissions. The company operates its head office in Oslo/Asker and maintains a test center in Svene, with additional branches in Wageningen and York. N2 Applied's scalable process aims to eliminate the lengthy and costly supply chains associated with traditional fertilizer production, facilitating a more circular farming system. This approach not only provides farmers with cost-effective and environmentally friendly fertilizer but also contributes to on-farm reductions in methane and ammonia emissions.

Iris.ai offers an AI-powered science assistant designed for R&D departments. It enhances research efficiency through smart search, filters, summaries, and autonomous extraction of scientific insights.

iLoF develops an AI-powered digital health platform that accelerates personalized drug discovery. It uses advanced photonics to collect data, building a digital library of biomarkers for studying tailored treatments and making clinical trials more efficient.

Arctic Therapeutics is a drug discovery and development company that focuses on identifying the genetic underpinnings of major and rare diseases. It employs bioinformatics and artificial intelligence to mitigate risks and reduce costs and development timelines in traditional drug development, while its research and development is guided by a global team of experts in genetics, genomics, immunology, bioinformatics, and drug development.

Arctic Therapeutics is a drug discovery and development company that focuses on identifying the genetic underpinnings of major and rare diseases. It employs bioinformatics and artificial intelligence to mitigate risks and reduce costs and development timelines in traditional drug development, while its research and development is guided by a global team of experts in genetics, genomics, immunology, bioinformatics, and drug development.

FreezeM is a company focused on advancing the use of insects as a sustainable protein source for the animal feed industry. Recognizing the potential of insects to address the growing demand for alternative protein, FreezeM develops innovative preservation technologies that facilitate large-scale freezing of insect species. This process aims to create a reliable supply of ready-to-use suspended neonates and frozen eggs, akin to agricultural seed production, which can overcome challenges related to availability, cost, and regulatory constraints. By establishing global stocks of beneficial insects, FreezeM supports various applications, including protein for animal feed, biological pest control, and species preservation, ultimately contributing to a more sustainable food system.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, established in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm specializes in developing advanced diagnostics for the early detection of various cancers, focusing on Stage I and Stage II malignancies where timely intervention can significantly improve patient outcomes. Utilizing a combination of infrared spectroscopy and artificial intelligence, Dxcover's technology enables the detection of cancer from a simple blood sample, allowing for same-day diagnosis and patient stratification. This innovative approach aims to enhance treatment options and ultimately improve survival rates and quality of life for patients.

iThera Medical develops biomedical imaging technology based on photonic molecular imaging and multispectral optoacoustic tomography (MSOT) for preclinical and clinical applications. The company leverages the photoacoustic effect to visualize and quantify anatomical, functional, and molecular information in vivo, including deep tissue visualization and real-time imaging, enabling non-invasive assessment of tumors and inflammatory diseases. Founded in 2010 as a spin-off from Helmholtz Zentrum München, iThera Medical focuses on advancing MSOT technology for use in preclinical research and clinical trials, supporting researchers and clinicians in obtaining deeper insights into biological processes without invasive procedures.

Founded in 2018, Resistell develops and markets a diagnostic device for phenotypic antibiotic susceptibility testing. Its unique method detects movement caused by living bacterial cells to determine bacterial resistance to antibiotics.

iOnctura is a biopharmaceutical company specializing in the development of novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which plays a significant role in cancer progression. The company seeks to enhance existing immune checkpoint therapies by creating new drugs that, when used in conjunction with these therapies, may improve safety and efficacy for cancer patients. iOnctura has formed strategic partnerships with prominent organizations, including Merck and Cancer Research Technology, to advance a pipeline of preclinical molecules toward clinical application. With access to advanced drug discovery labs and a network of academic collaborators, iOnctura is well-equipped to develop innovative combination therapies in the realm of cancer immunology, ultimately striving to optimize treatment outcomes for patients.

iOnctura is a biopharmaceutical company specializing in the development of novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which plays a significant role in cancer progression. The company seeks to enhance existing immune checkpoint therapies by creating new drugs that, when used in conjunction with these therapies, may improve safety and efficacy for cancer patients. iOnctura has formed strategic partnerships with prominent organizations, including Merck and Cancer Research Technology, to advance a pipeline of preclinical molecules toward clinical application. With access to advanced drug discovery labs and a network of academic collaborators, iOnctura is well-equipped to develop innovative combination therapies in the realm of cancer immunology, ultimately striving to optimize treatment outcomes for patients.

Odd.Bot is a technology company specializing in the development and manufacture of autonomous farming robots. Their flagship product, the Maverick robot, is designed to eliminate weeds in crops like carrots and onions without the use of chemicals. Operating around the clock, the robot effectively identifies and removes weeds in dense crops, promoting environmentally friendly agriculture.

Newronika develops innovative neuro-modulation devices aimed at restoring brain and body functions. The company translates its deep expertise in biosignal decoding into clinical practice, enabling patients to receive targeted stimulation for improved daily activities and enhanced quality of life.

ELEM Biotech SL is a biomedical software company based in Barcelona, Spain, that specializes in creating virtual human models through advanced mathematical modeling and cloud computing. Founded in 2018 by researchers from the Barcelona Supercomputing Center, ELEM has developed a suite of simulation tools known as Alya Red. This platform operates on a Software-as-a-Service model and is designed for the medical device and pharmaceutical industries. Alya Red allows for the simulation of cardiovascular and respiratory systems on virtual patients, utilizing high-performance computing, computational biomechanics, and data analysis. These virtual avatars enable biomedical companies and healthcare professionals to enhance diagnostics, plan treatments, optimize drug delivery, and improve medical devices.

FOx Biosystems is a biotechnology company focused on enhancing biomolecular interaction analysis for life science research and industry. Founded in 2017 by Filip Delport and Jeroen Lammertyn, and based in Temse, Oost-Vlaanderen, Belgium, the company specializes in developing custom applications, including probes and devices, to support various research needs. FOx Biosystems employs real-time, label-free analysis technology that offers significant advantages over traditional biomolecular analysis tools, such as ease of use, speed, and cost-effectiveness. This technology enables healthcare companies and researchers to obtain high-quality biomolecular data, including concentration measurements, affinity data, and kinetic data, ultimately aiming to transform the life sciences sector.

Protinhi Therapeutics is a preclinical stage biotechnology company focused on the development of antiviral drugs aimed at combating various viral threats, including dengue, Zika, and COVID-19. The company utilizes proprietary technology and compounds to create therapies that inhibit viral proteases, effectively preventing the viruses from replicating. This mechanism allows healthcare providers to better control the spread of these diseases, addressing significant public health challenges.

VIVAN Therapeutics pioneers personalized cancer therapeutics using innovative assay technology. It licenses technology from the Center for Personalized Cancer Therapeutics at Mount Sinai New York, offering a comprehensive, genomics-based drug screening service enabled by blockchain. The company's approach intelligently designs personalized treatments, combining cancer and non-cancer drugs to reduce toxicity and cost.

IDloop develops and sells a contactless fingerprint sensor solution, utilizing 3D imaging, AI, and embedded technology. This solution is designed for business and government markets, offering secure multi-finger image capture to enhance security services.

CorTec specializes in developing innovative medical devices for neuromodulation and brain-computer interfaces. Its flagship product is the CorTec Brain Interchange™ System, featuring flexible electrode arrays and a hermetically sealed electronics unit with custom microchip technology. The system enables permanent brain recordings and stimulation without the need for battery replacement surgery.

TENSIVE s.r.l. is a biomedical company based in Milan, Italy, founded in 2012. It specializes in the development of innovative prostheses for natural breast reconstruction and augmentation. The company's products utilize biodegradable synthetic biomaterials and feature an internal micro-architecture that mimics blood vessel structures. These vascularized prostheses aim to enhance the quality of life for patients undergoing treatment for breast cancer, offering a solution that reduces the need for recurrent and costly surgical interventions. Through its focus on advanced biomaterials and design, TENSIVE seeks to provide effective and sustainable options for breast reconstruction.

Actome specializes in developing emulsion coupling technology for life science research and personalized medicine. It uses proprietary technology to detect single protein molecules and protein interaction complexes, translating protein status into DNA barcodes using DNA-labeled antibodies.

Herantis Pharma is a biotech company focused on addressing unmet clinical needs, particularly in the field of neurodegenerative diseases. The company's primary development program centers on HER-096, a peptidomimetic molecule designed to mimic the biological activity of the neuroprotective CDNF protein. By targeting Parkinson's disease, Herantis Pharma aims to develop disease-modifying therapies that could significantly improve patient outcomes.

Precisis is a medical technology company founded in 2004 and headquartered in Heidelberg, Germany, focused on developing innovative devices for epilepsy treatment. The company designs a brain-computer interface device that delivers individualized brain stimulation by positioning beneath the scalp over the epileptic focus. The device enables deep, targeted stimulation of the affected brain region without direct contact with the skull or skull penetration, aiming to improve seizure control and quality of life for patients with epilepsy through precise anatomical targeting.

Herantis Pharma is a biotech company focused on addressing unmet clinical needs, particularly in the field of neurodegenerative diseases. The company's primary development program centers on HER-096, a peptidomimetic molecule designed to mimic the biological activity of the neuroprotective CDNF protein. By targeting Parkinson's disease, Herantis Pharma aims to develop disease-modifying therapies that could significantly improve patient outcomes.

Inbrain Neuroelectronics is a medical device company that designs and commercializes graphene-based neural interfaces and intelligent neuromodulation systems to treat brain disorders. The core platform is an implantable system that decodes brain activity with high resolution and provides focal, adaptive stimulation, enabling real-time precision neurology and autonomous therapy adjustments. This approach aims to maximize therapeutic outcomes while minimizing side effects for conditions such as Parkinson’s disease, epilepsy, and stroke rehabilitation. The company pursues strategic collaborations to extend its solutions to peripheral nerve and systemic disease applications, expanding the potential of neurotechnology and bioelectronics.

Elicit Plant is an agro-biotech company focused on enhancing crop resilience to water scarcity. It develops innovative phytosterol-based solutions that significantly reduce water stress in plants, enabling them to better withstand drought conditions.

Gate2Brain is an early-stage biotechnology company dedicated to enhancing drug delivery across biological barriers, with a focus on improving treatments for brain diseases. The company's proprietary technology employs peptide-based innovations to facilitate drug transport across barriers like the blood-brain barrier, aiming to increase treatment efficiency and minimize side effects.

Enduro Genetics is a technology provider that specializes in enhancing large-scale fermentations through its proprietary synthetic biology technology. The company focuses on improving the performance of fermentation processes by developing a genetic plugin technology that is free of antibiotic resistance genes. This innovation allows for higher yields by enriching spontaneous high producers within the fermentation population, facilitating the production of complex or cellular inhibit products by addressing strain instability. By maximizing the performance of cells derived from production strains, Enduro aims to bolster the competitiveness of both current and future green bioproduction initiatives.

ABCDx is a Geneva-based company that develops and validates biomarker panels and related diagnostics for brain injury care. It aims to identify patients at risk of severe long-term complications after traumatic brain injury or stroke and to educate clinicians on using these tests. The company is building a platform that analyzes brain biomarkers from a finger-prick blood sample to enable rapid, point-of-care diagnosis of brain injuries, supporting timely treatment decisions. Founded in 2014 by researchers from the University of Geneva and related institutes, ABCDx translates biomarker discovery and clinical validation into practical tools for stroke and brain injury management.

Alvus offers biomethane services. They offer project development, construction, and operation of biogas plants. They assist their customers in every aspect related to a biogas plant, due diligence analysis, business plan verification, site selection, biomass research, choice of power supply plan, selection of the most suitable technology.

Variolytics is a developer of advanced measurement technologies, specializing in mass spectrometry for environmental applications, particularly in sewage treatment plants. The company focuses on measuring all gas components, including greenhouse gases, within aeration tanks. Variolytics offers a range of products including measuring devices, sensor technologies, and monitoring systems that facilitate accurate data collection and process integration. In addition to its innovative measurement solutions, the company conducts process engineering research and development, providing expert advice and implementation services to help businesses optimize their industrial processes. By delivering insights into process dynamics, Variolytics enables companies to make informed decisions and enhance operational efficiency.

Inbrain Neuroelectronics is a medical device company that designs and commercializes graphene-based neural interfaces and intelligent neuromodulation systems to treat brain disorders. The core platform is an implantable system that decodes brain activity with high resolution and provides focal, adaptive stimulation, enabling real-time precision neurology and autonomous therapy adjustments. This approach aims to maximize therapeutic outcomes while minimizing side effects for conditions such as Parkinson’s disease, epilepsy, and stroke rehabilitation. The company pursues strategic collaborations to extend its solutions to peripheral nerve and systemic disease applications, expanding the potential of neurotechnology and bioelectronics.

Xenikos develops innovative immunotherapy medicines using anti-T-cell antibodies. These therapies aim to reset patients' immune systems quickly and efficiently, targeting activated adult T cells to improve treatment outcomes for serious immune diseases.

Novus Diagnostics develops a point-of-care diagnostic system for infectious diseases, including a sample-to-answer sepsis platform that rapidly detects and classifies pathogens in whole blood. The device provides automated pathogen identification within minutes from a blood sample, allowing healthcare providers to diagnose sepsis-related infections and initiate timely, cost-effective treatment.

Cherry Biotech is a biomedical technology company that develops Organ on Chip instruments and microfluidic systems to culture and mimic human organs under physio-pathological conditions for drug discovery and personalized medicine. The company also offers temperature controllers for rapid temperature shifts and next-generation 3D cell culture technologies to recreate the human cell microenvironment, supporting drug development and toxicity assessment.

Founded in 2019, Arthex Biotech is a Spanish biotechnology company specializing in the development of antisense RNA therapies for genetic diseases. The company, spun off from the University of Valencia, leverages its team's expertise in drug discovery and microRNAs to create innovative treatments.

Meletios Therapeutics is a biotechnology company focused on developing antiviral molecules to address both current and emerging diseases. The company specializes in creating antiviral drugs that target the host mechanisms exploited by viruses, thereby providing healthcare institutions with effective treatment options for a variety of pathologies. Through its innovative approach, Meletios Therapeutics aims to fulfill critical medical needs in the realm of antiviral therapeutics.